Dediabetes Logo
Preguntas
Respuestas publicadas conectadas con evidencia
Referencia clínica
Dossieres detallados de intervenciones y resultados
Investigacion reciente
Estudios mas recientes
Acerca de
Cómo funciona deDiabetes
Configuracion
Entrar / Unirse

SGLT2 Inhibitors for Diabetes: Evidence and Outcomes

Ver informe de evidencia

Evidence on outcomes studied for SGLT2 Inhibitors

Evidence related to SGLT2 inhibitor therapies in diabetes studies.

Crea tu Evidence Workspace

Guarda evidencia sobre los temas que te importan.

41
Studies
100
Evidence Pairs
Moderate Evidence
Evidence Strength: 63/100
Evidence Intelligence™

Evidence Summary

A structured summary of where the evidence is strongest, mixed, or still emerging.

Executive Summary

SGLT2 Inhibitors evidence appears to center on HbA1c.

Among 41 indexed studies and 4 interventions, the strongest signals are summarized from the available evidence. HbA1c appears to be one of the clearer current evidence signals.

  • Evidence is consistently positive across multiple studies.
  • Some evidence is positive, but results are not consistent across all studies.
  • Early findings are encouraging, but stronger trials are needed.
Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Key Finding

Evidence is consistently positive across multiple studies.

Interventions with strongest consistent evidence

Strongest consistent evidence

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

HbA1c appears to have a consistent beneficial signal in the indexed evidence.

View supporting studies
Evidence basis: 16 evidence pairs - 31 studies

Why this appears here

Strong evidenceConsistent resultsPositive effect signalMultiple RCTsModerate evidence
HbA1c
25 studies
EvidenceScore™
85/100
ConsistencyScore™
82/100
Urinary albumin-to-creatinine ratio
7 studies
EvidenceScore™
78/100
ConsistencyScore™
100/100

Evidence Snapshot

41
Studies
4
Interventions
79
Outcomes
4
Strong evidence signals
1
Mixed evidence areas

Key Findings

Key patterns and insights identified across the research landscape

Strong positive signal

HbA1c

Across 10 studies, Empagliflozin shows a consistent strong positive signal for HbA1c.

10 studies
EvidenceScore™: 84.93846153846154/100
View supporting studies
Moderate positive signal

Fasting Plasma Glucose (FPG)

Across 5 studies, Empagliflozin shows a consistent moderate positive signal for Fasting Plasma Glucose (FPG).

5 studies
EvidenceScore™: 83.06153846153846/100
View supporting studies
Evidence signal

Body weight

Across 6 studies, Empagliflozin shows a consistent evidence signal for Body weight.

6 studies
EvidenceScore™: 82.94871794871796/100
View supporting studies
Moderate positive signal

HbA1c

Across 9 studies, Dapagliflozin shows a consistent moderate positive signal for HbA1c.

9 studies
EvidenceScore™: 82.4625759596858/100
View supporting studies
Moderate positive signal

HbA1c

Across 3 studies, Canagliflozin shows a moderate positive signal for HbA1c.

3 studies
EvidenceScore™: 79/100
View supporting studies

Supporting Evidence

Mixed or conflicting evidence

Some evidence is positive, but results are not consistent across all studies.

Areas where results are mixed

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

HbA1c is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Top entities

HbA1c
Body weight
HbA1c
25 studies
EvidenceScore™
85/100
ConsistencyScore™
82/100

Why this appears here

Mixed Or Conflicting ResultsPositive Signal PresentNeutral Results Present
Evidence basis: 15 evidence pairs - 29 studies
View supporting studies
Promising but understudied

Early findings are encouraging, but stronger trials are needed.

Promising areas needing more evidence

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Triglycerides may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Top entities

Triglycerides
Alanine Aminotransferase (ALT)
Triglycerides
3 studies
EvidenceScore™
72/100
ConsistencyScore™
100/100

Why this appears here

Positive effect signalLimited study volume
Evidence basis: 7 evidence pairs - 11 studies
View supporting studies

Explore the Evidence

The sections below provide the complete evidence questions, supporting relationships, and underlying studies behind the summary above.

Preguntas respondidas por la evidencia

What outcomes has SGLT2 Inhibitors been studied for?

HbA1c, Fasting Plasma Glucose (FPG), and Body weight are among the most studied areas in relation to SGLT2 Inhibitors.

Emerging Evidence · Consistency cannot yet be determined from the available evidence. · 41 studies · 40 RCTs

View top evidence signals ↓
  1. HbA1c · Strong · 25 studies
  2. Fasting Plasma Glucose (FPG) · Strong · 9 studies
  3. Body weight · Strong · 9 studies

Do SGLT2 Inhibitors lower HbA1c?

SGLT2 Inhibitors may lower HbA1c.

Strong Evidence · Results are consistent across studies. · 25 studies · 24 RCTs

View top evidence signals ↓
  1. HbA1c · Strong · 25 studies

Do SGLT2 Inhibitors affect body weight?

SGLT2 Inhibitors may affect body weight.

Strong Evidence · Results are consistent across studies. · 9 studies · 9 RCTs

View top evidence signals ↓
  1. Body weight · Strong · 9 studies

Which outcomes have the strongest evidence for SGLT2 Inhibitors?

HbA1c, Fasting Plasma Glucose (FPG), and Body weight have the strongest available evidence signals for SGLT2 Inhibitors.

Strong Evidence · Results are consistent across studies. · 30 studies · 29 RCTs

View top evidence signals ↓
  1. HbA1c · Strong · 25 studies
  2. Fasting Plasma Glucose (FPG) · Strong · 9 studies
  3. Body weight · Strong · 9 studies

Where does SGLT2 Inhibitors need more research?

Reduction in Hemoglobin A1C levels, Fasting blood sugar (FBS), and Glucose iAUC (OGTT) need more research in relation to SGLT2 Inhibitors.

Moderate Evidence · Results are consistent across studies. · 9 studies · 9 RCTs

View top evidence signals ↓
  1. Fasting blood sugar (FBS) · Moderate · 2 studies
  2. Reduction in Hemoglobin A1C levels · Moderate · 2 studies
  3. Glucose iAUC (OGTT) · Moderate · 2 studies
Browse all questions about SGLT2 Inhibitors

Overall Evidence Signals

Among 41 indexed studies and 4 interventions, the strongest signals are summarized from the available evidence. HbA1c appears to be one of the clearer current evidence signals.

  • Evidence is consistently positive across multiple studies.
  • Some evidence is positive, but results are not consistent across all studies.
  • Early findings are encouraging, but stronger trials are needed.

Evidence Relationships

Explore the intervention-outcome relationships with the strongest supporting evidence for SGLT2 Inhibitors.

8 strong relationships, ranked by available evidence

Select any relationship to review its supporting studies.

Studies evaluating SGLT2 Inhibitors

Studies connected to this intervention in the evidence record.

Click outcomes and interventions to filter Evidence Explorer when links are available.

Continue exploring

Related evidence briefs

Diabetic Kidney Disease

Evidence Tracker

Track SGLT2 Inhibitors for Diabetes: Evidence and Outcomes evidence

Save this evidence topic and revisit it as new studies are added.